Treatment of Restrictive Cardiomyopathy
The treatment of restrictive cardiomyopathy must be tailored to the underlying etiology, with tafamidis for ATTR-CM, chemotherapy ± autologous stem cell transplantation for AL amyloidosis, and supportive heart failure management with diuretics as the cornerstone for all RCM patients, while avoiding β-blockers, ACE inhibitors, ARBs, calcium channel blockers, and digoxin due to poor tolerability and potential toxicity. 1
Disease-Specific Treatment Pathways
For ATTR Cardiac Amyloidosis
- Tafamidis is the disease-modifying therapy of choice for transthyretin amyloid cardiomyopathy, with demonstrated improvements in cardiac function, survival, functional capacity, and quality of life 1, 2
- Genetic sequencing must be performed to differentiate hereditary ATTR (hATTR) from wild-type ATTR (wtATTR), as this determines prognosis, extracardiac involvement risk, family screening needs, and eligibility for novel therapies 1
- Emerging therapies under investigation include:
For AL (Light Chain) Amyloidosis
- Chemotherapy with or without autologous stem cell transplantation (ASCT) is the primary disease-modifying approach 1
- Tissue biopsy confirmation is mandatory for diagnosis 1
- Bone marrow biopsy is often performed to exclude concurrent multiple myeloma 1
- Abdominal fat pad biopsy has variable yield (15-84%, highest for AL) but can obviate endomyocardial biopsy when positive and combined with imaging evidence 1
For Other Infiltrative RCM
- Cardiac sarcoidosis and cardiac hemochromatosis require disease-specific interventions when identified early 4
- Endomyocardial biopsy may be necessary to confirm diagnosis in suspected myocarditis and infiltrative diseases 5
Heart Failure Symptom Management (All RCM Types)
Primary Approach
- Dietary sodium restriction and aggressive diuresis are the mainstay of supportive management 1
- Use loop diuretics as first-line, adding mineralocorticoid receptor antagonists and thiazide diuretics as needed for adequate decongestion 1
Critical Medications to AVOID or Use with Extreme Caution
The restrictive physiology and autonomic dysfunction in cardiac amyloidosis lead to poor tolerability of standard heart failure medications:
- β-blockers: Use with considerable caution or avoid - poorly tolerated due to restrictive physiology 1
- ACE inhibitors and ARBs: Use with considerable caution or avoid - frequently poorly tolerated 1
- Calcium channel blockers: Avoid if possible - increased risk of local toxicity 1
- Digoxin: Avoid if possible - increased risk of local toxicity 1
Common Pitfall
Many clinicians reflexively prescribe standard heart failure medications (β-blockers, ACE inhibitors) in RCM patients. This is a critical error - these agents worsen symptoms and outcomes in restrictive cardiomyopathy due to the unique pathophysiology of diastolic dysfunction and autonomic impairment.
Advanced Therapies for Refractory Disease
Heart Transplantation
- Consider in carefully selected patients with refractory heart failure symptoms 1
- Contemporary data show outcomes in selected ATTR and AL patients are similar to other transplant recipients 1
- Selection criteria typically exclude clinically relevant extracardiac involvement 1
- For AL patients, ASCT can be performed after successful heart transplantation at some centers 1
- Heart transplantation may be the definitive treatment for symptomatic idiopathic RCM given poor evolution with medical or surgical therapy alone 6
Surgical Considerations
- Tricuspid valve repair (De Vega plasty) may be performed for significant tricuspid regurgitation, though this does not alter the poor overall prognosis 6
- Cardiac catheterization combined with non-invasive imaging helps establish diagnosis in suspected constrictive vs. restrictive cardiomyopathy 5
Diagnostic Confirmation Requirements
Before initiating treatment, proper diagnosis is essential:
- Endomyocardial biopsy shows interstitial fibrosis, myocyte hypertrophy, and myofibril disarray in idiopathic RCM 6
- Hemodynamic study demonstrates elevated right ventricular pressure, elevated left ventricular end-diastolic pressure, and elevated pulmonary capillary wedge pressure 6
- The restrictive pattern (dip and plateau) on cardiac catheterization is diagnostic 6
Prognostic Considerations
- Early recognition remains the key barrier to improving survival across all RCM types 4
- RCM has remained a modest area of research interest, though the therapeutic landscape is evolving with novel targeted therapies 3
- Sarcomeric variants carry worse prognosis with lower transplant-free survival and higher thrombotic event rates compared to non-sarcomeric RCM 7
- The disease has poor evolution overall, even with clinical or surgical treatment, making early diagnosis and appropriate disease-specific therapy critical 6